Skip to main content
SpringerLink
Log in

The value of non-human primates in the development of monoclonal antibodies

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Average use of NHP per nonclinical programs increases as the mAb in development becomes more human.

References

  1. Teelmann, K., Hohbach, C. & Lehmann, H. Arch. Toxicol. 59, 195–200 (1986).

    Article  CAS  Google Scholar 

  2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf (ICH, 1997).

  3. Bailey, J., Capaldo, T., Conlee, K., Thew, M. & Pippin, J. Nat. Med. 14, 1011–1012; discussion 1012–1013 (2008).

    Article  CAS  Google Scholar 

  4. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124 (EMA, 2008).

  5. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124# (EMA, 2006).

  6. Fraser, H.M. & Wulff, C. Reprod. Biol. Endocrinol. 1, 88 (2003).

    Article  Google Scholar 

  7. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000972/WC500051808.pdf (EMA, 2009).

  8. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001109/WC500031679.pdf (EMA, 2009).

  9. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf (EMA, 2007).

  10. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000353/WC500025264.pdf (EMA, 2005).

  11. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001037/WC500069735.pdf (EMA, 2009).

  12. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000603/WC500044690.pdf (EMA, 2007).

Download references

Acknowledgements

This research is part of Top Institute Pharma project T6-301. P.J.K.v.M. and M.K. performed this work with the TIP grant. The views expressed in this article are the personal views of the authors and are not to be understood or quoted as being made on behalf of or reflecting the position of the Medicines Evaluation Board or any other regulatory agency, or one of its committees or working parties.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

    P J K van Meer & H Schellekens

  2. Copernicus Institute of Sustainable Development, Innovation Studies, Utrecht University, Utrecht, The Netherlands

    M Kooijman, E H M Moors & H Schellekens

  3. Medicines Evaluation Board, Utrecht, The Netherlands

    J W van der Laan

Authors
  1. P J K van Meer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kooijman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J W van der Laan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E H M Moors
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Schellekens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P J K van Meer.

Ethics declarations

Competing interests

H.S. participated in meetings and publications sponsored by Amgen, J&J, Roche, Sandoz and Hospira. Part of his research is also directly or indirectly sponsored by Amgen, Roche and Sandoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Meer, P., Kooijman, M., van der Laan, J. et al. The value of non-human primates in the development of monoclonal antibodies. Nat Biotechnol 31, 882–883 (2013). https://doi.org/10.1038/nbt.2709

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2709

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation